Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Abbott raises earnings outlook as MedTech, Pharma drive Q3 beat
Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Tuesday after its financials for Q3 2024 exceeded Wall Street's forecasts, thanks mainly to the strength in its Pharma and MedTech segments.
Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company’s medical-devices business.
Abbott Laboratories Q3 Profit Increases, Beats Estimates
Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks Consensus Estimate by 0.8%. The figure also improved 6.1% from the prior-year quarter’s level.
ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
Abbott ($ABT) reported better-than-expected third-quarter results on Wednesday. The medical devices and healthcare company’s sales increased by
Abbott Q3: Strong Growth In Medical Device And Pharma
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read an analysis of ABT stock now.
Abbott Laboratories Narrows Full-Year Earnings Outlook Range Following Third-Quarter Beat
Abbott Laboratories (ABT) reported better-than-expected third-quarter results on Wednesday amid double-digit revenue growth in its medical devices segment, while the healthcare company narrowed its full-year earnings outlook range.
8h
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...
Becker's Spine Review
6h
8 medtech notes: Aurora Spine, SI-Bone and more
Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...
2d
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...
4h
China Plus One? MedTech’s search for adaptable supply chain models
Industry leaders explored the risks and benefits of adopting a China Plus One strategy at Advamed’s The MedTech Conference in ...
ENDPOINTS NEWS
1d
J&J’s medtech slump continues, improvements not expected until 2025
Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the ...
Medical Design and Outsourcing
5d
The 10 largest medtech employers of 2024 – and what their employees really think
Employees at the 10 largest medtech employers in the world are excited about culture but are still frustrated by corporate ...
8d
on MSN
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%. The company’s non-MedTech operations are ...
15h
Nodenza Venture Partners launched - focus on international early-stage and pre-commercial biotech & medtech opportunities
Nodenza Venture Partners launchedFocus on international early-stage and pre-commercial biotech & medtech opportunitiesNew York, October 16, ...
FierceBiotech
6d
Drive Growth and Optimize Margins with a Tailored MedTech Contract Sales Solution
Authors:Kirk Harmon, Vice President & GM, Contract Sales Organization, IQVIAJavier “Jave” Castillo, R.Ph, Vice President, CSO ...
Medical Design and Outsourcing
2d
Infor Cloverleaf joins with Nvidia Holoscan for AI-powered medtech
The Infor Cloverleaf Data Integration Platform is now interoperable with the Nvidia Holoscan AI platform, providing more AI ...
EPT
1d
MedTech conference kicks off in Toronto
Event puts focus on medical technologies Oct. 15-17 at the Metro Toronto Convention Centre ...
FierceBiotech
1d
How will regulators adapt to adaptive AI?
TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Q3
Johnson & Johnson
Abbott Laboratories
Health technology
Feedback